Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Tofogliflozin hydrate (CSG-452 hydrate) 是一种有效的,选择性的 SGLT2抑制剂,IC50为 2.9 nM,对人、大鼠和小鼠 SGLT2的Ki 分别为 2.9 nM,14.9 nM 和 6.4 nM。Tofogliflozin hydrate 对肾小管细胞中高葡萄糖诱导的ROS 生成具有部分抑制作用。
规格 | 价格/CNY | 货期 | 数量 | |
---|---|---|---|---|
1 mg | ¥ 333 | 现货 | ||
2 mg | ¥ 482 | 现货 | ||
5 mg | ¥ 796 | 现货 | ||
10 mg | ¥ 1,230 | 现货 | ||
25 mg | ¥ 2,390 | 现货 | ||
50 mg | ¥ 3,570 | 现货 | ||
100 mg | ¥ 5,120 | 现货 | ||
200 mg | ¥ 6,920 | 现货 | ||
500 mg | ¥ 9,870 | 现货 | ||
1 mL * 10 mM (in DMSO) | ¥ 738 | 现货 |
产品描述 | Tofogliflozin hydrate (CSG-452 hydrate) is a potent and highly specific inhibitor of SGLT2(IC50 of 2.9 nM and Ki values of 2.9 nM, 14.9 nM, and 6.4 nM for human, rat, and mouse SGLT2). |
靶点活性 | SGLT2 (rat):14.9 nM(Ki) , SGLT2:2.9 nM , SGLT2:6.4 nM(Ki), SGLT2 (human):2.9 nM(Ki) |
体外活性 | Tofogliflozin, a highly selective inhibitor of SGLT2 on oxidative stress generation, inflammatory and proapoptotic reactions in cultured human proximal tubular cells exposed to high glucose.?Tofogliflozin dose-dependently suppressed glucose entry into tubular cells.?High glucose exposure (30 mM) for 4 and 24 h significantly increased oxidative stress generation in tubular cells, which were suppressed by the treatment of tofogliflozin or an antioxidant N-acetylcysteine (NAC).?Monocyte chemoattractant protein-1 (MCP-1) gene expression and apoptotic cell death were induced by 4 h- and 8 day-exposure to high glucose, respectively, both of which were also blocked by tofogliflozin or NAC.?The present study suggests that SGLT2-mediated glucose entry into tubular cells could stimulate oxidative stress and evoke inflammatory and proapoptotic reactions in this cell type.?Blockade of glucose reabsorption in tubular cells by SGLT2 inhibitor might exert beneficial effects on tubulointerstitial damage in diabetic nephropathy[1]. |
别名 | 托格列净, Tofogliflozin hydrate, CSG-452 hydrate |
分子量 | 404.45 |
分子式 | C22H28O7 |
CAS No. | 1201913-82-7 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
H2O: 0.33 mg/mL (0.82 mM), Sonication is recommended.
DMSO: 90 mg/mL (222.52 mM)
可选溶剂 | 浓度 体积 质量 | 1 mg | 5 mg | 10 mg | 25 mg |
DMSO | 1 mM | 2.4725 mL | 12.3625 mL | 24.7249 mL | 61.8123 mL |
5 mM | 0.4945 mL | 2.4725 mL | 4.945 mL | 12.3625 mL | |
10 mM | 0.2472 mL | 1.2362 mL | 2.4725 mL | 6.1812 mL | |
20 mM | 0.1236 mL | 0.6181 mL | 1.2362 mL | 3.0906 mL | |
50 mM | 0.0494 mL | 0.2472 mL | 0.4945 mL | 1.2362 mL | |
100 mM | 0.0247 mL | 0.1236 mL | 0.2472 mL | 0.6181 mL |
对于不同动物的给药剂量换算,您也可以参考 更多...
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法: 比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL,一共给药动物10 只,您使用的配方为5% DMSO+30% PEG300+5% Tween 80+60% ddH2O。那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 50 μL DMSO (母液浓度为 40 mg/mL), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法:取 50 μL DMSO 主液,加入 300 μL PEG300, 混匀澄清,再加 50 μL Tween 80,混匀澄清,再加 600 μL ddH2O, 混匀澄清。
您可能有的问题的答案可以在抑制剂处理说明中找到,包括如何准备库存溶液,如何存储产品,以及基于细胞的分析和动物实验需要特别注意的问题。
Tofogliflozin (hydrate) 1201913-82-7 GPCR/G Protein Immunology/Inflammation Metabolism NF-Κb SGLT Reactive Oxygen Species ROS Tofogliflozin Hydrate inhibit CSG 452 Hydrate 托格列净 CSG 452 Inhibitor CSG452 CSG-452 CSG452 Hydrate Tofogliflozin Sodium-dependent glucose cotransporters CSG-452 Hydrate Tofogliflozin hydrate CSG-452 hydrate inhibitor